Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 17/20 | 0.35 |
| ▸ | FPR3 | P25089 | 14/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2683203 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2FPR2FPR3PKM | |
| SCHEMBL16674043 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2FPR2FPR3PKM | |
| SCHEMBL16377662 | 0.95 | PKM (0.39) | SMN1; SMN2FPR2FPR3PKM | |
| SCHEMBL2683926 | 0.77 | PPM1B (0.47) | SMN1; SMN2FPR2FPR3PKM | |
| SCHEMBL10224384 | 0.77 | PPM1B (0.47) | SMN1; SMN2FPR2FPR3PKM | |
| SCHEMBL2685419 | 0.77 | PPM1B (0.47) | SMN1; SMN2FPR2FPR3PKM | |
| SCHEMBL2682902 | 0.77 | PPM1B (0.47) | SMN1; SMN2FPR2FPR3PKM | |
| SCHEMBL14899318 | 0.68 | ALDH1A1 (0.47) | SMN1; SMN2 | |
| SCHEMBL6899724 | 0.68 | ALDH1A1 (0.47) | SMN1; SMN2 | |
| SCHEMBL6900291 | 0.67 | ALDH1A1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2432760-A1 | BRIDGED SPIRO [2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010134014-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-25 | — | — | WO | disclosed |